Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04271540 · ClinicalTrials.gov registry record · Phase 4
MIcrovascular dysfuNction In Moderate-severe Psoriasis
A Phase 4 study of Cardiovascular Disease and Psoriasis, sponsored by Marcelo F. Di Carli, MD, FACC.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04271540 is a Phase 4 study of Cardiovascular Disease and Psoriasis that has completed, run by Marcelo F. Di Carli, MD, FACC. The registered enrollment target is 36 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04271540, a Phase 4 study of Cardiovascular Disease and Psoriasis, has completed, sponsored by Marcelo F. Di Carli, MD, FACC.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk. Despite the implication of inflammation in this excess risk, it remains unclear whether reducing inflammation reduces the risk of cardiac events. This study proposes to test whether Tildrakizumab, an FDA approved therapy for psoriasis that blocks IL-23 and the Th17 pathway of inflammation, improves coronary vascular function and coronary flow reserve, as measured by noninvasive imaging with cardiac positron emission tomography. In so doing, improvement in coronary vasoreactivity, endothelial function, and tissue perfusion may have beneficial effects on myocardial mechanics, left ventricular deformation and function and, ultimately, symptoms and prognosis. This research may offer novel insights into the contributors of CV risk in psoriasis and provide data to support the development of strategies to prevent cardiovascular events in psoriatic disease.
Conditions Studied
Interventions
- DRUG Tildrakizumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-04-04 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04271540
The ClinicalTrials.gov registry entry for NCT04271540 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The listed sponsor is Marcelo F. Di Carli, MD, FACC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Tildrakizumab is the first listed.
NCT04271540 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04271540 about?
NCT04271540 is a clinical study titled "MIcrovascular dysfuNction In Moderate-severe Psoriasis". Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk. Despite the implication of inflammation in this excess risk, it remains unclear whether reducing inflammation reduces the risk of cardiac events....
What is the current status of trial NCT04271540?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2020-04-04. Estimated completion is 2024-07-17.
What conditions does trial NCT04271540 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Psoriasis.
What interventions are being tested in trial NCT04271540?
The interventions under investigation include: Tildrakizumab (DRUG).
Who is sponsoring clinical trial NCT04271540?
This trial is sponsored by Marcelo F. Di Carli, MD, FACC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04271540 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
RECRUITING · Phase 4
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.